DFTX
Definium Therapeutics, Inc.
There isn't enough reported data to score DFTX yet.
DFTX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
DFTX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
DFTX PE Valuation
DFTX has no meaningful PE right now: it lost money over the past year.
DFTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| -- | |
| -- | |
| Limited | |
| Moderate |
Analysts expect DFTX's earnings, revenue and profitability to hold roughly steady.
DFTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.04 | -$0.98 |
| Q2 2026 | -$3.36 | -$1.81 |
| Q1 2026 | -$2.42 | -$1.11 |
| Q4 2025 | -$2.06 | +$0.04 |
| Q3 2025 | -$2.06 | +$0.19 |
| Q2 2025 | -$1.55 | +$0.88 |
| Q1 2025 | -$1.31 | +$1.62 |
| Q4 2024 | -$2.10 | +$0.34 |
DFTX is still losing money, but far less than before: $3.04 per share over the past year, against $6.08 at its worst in early 2022.
DFTX Quarterly Revenue
DFTX's revenue is shrinking: $0 last quarter.
DFTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$53M | -$23.4M |
| Q2 2026 | -$52.8M | -$23.2M |
| Q1 2026 | -$42.6M | -$13.2M |
| Q4 2025 | -$43M | -$17.6M |
| Q3 2025 | -$29.6M | -$12.4M |
| Q2 2025 | -$29.6M | -$9.6M |
| Q1 2025 | -$29.4M | -$12.8M |
| Q4 2024 | -$25.4M | -$4.8M |
DFTX has burned cash in almost every quarter: −$191M over the past year, against −$114M the year before.
DFTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +24% | +26.7M shares |
| 1 year | +60% | +51.5M shares |
| 3 years | +246% | +97.6M shares |
| 5 years | +390% | +109M shares |
| Available history | +616% | +118M shares |
DFTX has 137M diluted shares, up 60% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
DFTX Net Leverage
DFTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
DFTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.8 | Neutral |
| Stochastic | 18.9 | Oversold |
DFTX's weekly RSI is 48 (neutral) and its Stochastic is 19 (oversold).
DFTX PE vs Healthcare Sector
DFTX has no meaningful PE right now: it lost money over the past year.
DFTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $35.1 | 6% below |
| 20 week MA | $39.7 | 17% below |
| 50 week MA | $27.5 | 20% above |
| 100 week MA | $18.0 | 83% above |
| 200 week MA | $11.7 | 183% above |
DFTX has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 183% above its 200-week average.
DFTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.72 | $45.2 | +6171% |
| 2021 | $45.2 | $25.4 | -44% |
| 2022 | $25.4 | $2.53 | -90% |
| 2023 | $2.53 | $3.66 | +45% |
| 2024 | $3.66 | $6.84 | +87% |
| 2025 | $6.84 | $13.1 | +91% |
| 2026 YTD | $13.1 | $33.0 | +153% |
DFTX's yearly returns have swung widely, from +6171% in 2020 to −90% in 2022. It's up 153% so far in 2026.